Francesca Aroldi

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC).

A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC).

Journal: BMC cancer

Published: February 11, 2025

A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301).

A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301).

Journal: Journal of experimental & clinical cancer research : CR

Published: November 09, 2023

Lag3: From Bench to Bedside.

Lag3: From Bench to Bedside.

Journal: Cancer treatment and research

Published: May 13, 2022

Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma.

Long-Term Outcomes of Immune Checkpoint Inhibition in Metastatic Melanoma.

Journal: American journal of clinical dermatology

Published: March 01, 2022

CHK1 inhibition exacerbates replication stress induced by IGF blockade.

CHK1 inhibition exacerbates replication stress induced by IGF blockade.

Journal: Oncogene

Published: May 04, 2021

Poor efficacy of palbociclib in second-line treatment of metastatic lobular breast cancer in a case series: Use before or never more?

Poor efficacy of palbociclib in second-line treatment of metastatic lobular breast cancer in a case series: Use before or never more?

Journal: The breast journal

Published: December 01, 2019

Window of opportunity clinical trial designs to study cancer metabolism.

Window of opportunity clinical trial designs to study cancer metabolism.

Journal: British journal of cancer

Published: June 16, 2019

Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.

Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.

Journal: Journal of cellular physiology

Published: October 10, 2018

Immunotherapy for pancreatic cancer: present and future.

Immunotherapy for pancreatic cancer: present and future.

Journal: Immunotherapy

Published: June 10, 2017

Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.

Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.

Journal: Gastroenterology

Published: March 06, 2017

Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?

Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?

Journal: Journal of chemotherapy (Florence, Italy)

Published: December 30, 2016

Current Role of Minimally Invasive Radical Cholecystectomy for Gallbladder Cancer.

Current Role of Minimally Invasive Radical Cholecystectomy for Gallbladder Cancer.

Journal: Gastroenterology research and practice

Published: July 21, 2016

Showing 1-12 of 24

Last Updated: 09/26/2026